Table 1 Demographics, CV medication experience and HAART effectiveness in three different time periods
From: Consistent use of lipid lowering therapy in HIV infection is associated with low mortality
Baseline characteristics over time (Median (IQR) or %) | 1996–2000 | 2001–2005 | 2006–2011 | Overall |
|---|---|---|---|---|
n = 7434 | n = 7855 | n = 7987 | n = 23,276 | |
Age | 50 (44–56) | 53 (47–60) | 56 (48–64) | 53 (46–60) |
Female | 1.9% | 2.4% | 3.3% | 2.5% |
Race | ||||
 African American | 38% | 48% | 53% | 46% |
 White | 34% | 39% | 37% | 37% |
 Unknown | 27% | 12% | 8% | 15% |
Smoking | 52% | 59% | 57% | 56% |
HCV co-infection | 34% | 27% | 19% | 26% |
CD4 (/mm3) | 312 (170–486) | 312 (176–484) | 355 (220–512) | 328 (189–496) |
VL LOG before HAART | 4.2 (3.3–4.9) | 4.6 (3.5–5.2) | 4.5 (3.5–5.0) | 4.4 (3.4–5.0) |
Years HIV Diagnosis-VL suppression | 2.9 (0.9–5.3) | 3.4 (0.9–7.4) | 2.9 (0.8–7.9) | 3.0 (0.9–6.6) |
Prior CV Medication Exposure | ||||
 LLT | 2% | 9% | 12% | 8% |
 AHT | 17% | 25% | 30% | 24% |
 ASA | 4% | 6% | 6% | 5% |
HAART at study inclusion | ||||
 None | 7% | 12% | 4% | 8% |
 Unboosted PI, no TDF | 76% | 19% | 3% | 32% |
 Unboosted PI with TDF | 0% | 3% | 2% | 2% |
 Boosted PI, no TDF | 5% | 17% | 13% | 12% |
 Boosted PI with TDF | 0% | 11% | 25% | 12% |
 EFV or INSTI, no TDF | 12% | 29% | 12% | 18% |
 EFV or INSTI with TDF | 0% | 9% | 41% | 17% |
One-year HAART adherence (Median) | 65% | 74% | 84% | 79% |
One-year virologic suppression (Mean) | 75% | 70% | 83% | 78% |